SPX3,971.68+37.76 0.96%
DIA339.34+2.90 0.86%
IXIC11,109.99+151.43 1.38%

BMO Capital Maintains Outperform on Immunogen, Raises Price Target to $19

Benzinga · 11/16/2022 07:02
BMO Capital analyst Etzer Darout maintains Immunogen (NASDAQ:IMGN) with a Outperform and raises the price target from $17 to $19.